News

Merck's $3B Shock Move: Is This the End of the Keytruda Era?

Shipments to China are now paused through the end of 2025, dragging global sales of the HPV vaccine down 55% last quarter.
BioSpace16h

Merck’s $3B Savings Push Claims 6,000 Jobs

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...
Fierce Pharma3d

Merck joins Big Pharma cost-cutting crowd, revealing plan to save $3B annually by 2027

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...

Merck extends pause on China Gardasil shipments to year end, shares slip

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Merck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim Cramer

We recently published 13 Stocks That Jim Cramer Recently Talked About. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed.

Merck to extend pause on China Gardasil shipments to year end

Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to ...

Merck’s (NYSE:MRK) Q2 Earnings Results: Revenue In Line With Expectations

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...